Galon et al., 2014 - Google Patents
Towards the introduction of the 'Immunoscore'in the classification of malignant tumoursGalon et al., 2014
View PDF- Document ID
- 9891959268737051576
- Author
- Galon J
- Mlecnik B
- Bindea G
- Angell H
- Berger A
- Lagorce C
- Lugli A
- Zlobec I
- Hartmann A
- Bifulco C
- Nagtegaal I
- Palmqvist R
- Masucci G
- Botti G
- Tatangelo F
- Delrio P
- Maio M
- Laghi L
- Grizzi F
- Asslaber M
- D'Arrigo C
- Vidal‐Vanaclocha F
- Zavadova E
- Chouchane L
- Ohashi P
- Hafezi‐Bakhtiari S
- Wouters B
- Roehrl M
- Nguyen L
- Kawakami Y
- Hazama S
- Okuno K
- Ogino S
- Gibbs P
- Waring P
- Sato N
- Torigoe T
- Itoh K
- Patel P
- Shukla S
- Wang Y
- Kopetz S
- Sinicrope F
- Scripcariu V
- Ascierto P
- Marincola F
- Fox B
- Pagès F
- Publication year
- Publication venue
- The Journal of pathology
External Links
Snippet
Abstract The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging …
- 201000011510 cancer 0 title abstract description 73
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Galon et al. | Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours | |
| Conway et al. | Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’out of ‘CUP’ | |
| Huang et al. | Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling | |
| Spira et al. | Precancer atlas to drive precision prevention trials | |
| Masuda et al. | Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes | |
| Nassar et al. | Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma | |
| Jensen et al. | Molecular profiling of tumour budding implicates TGFβ‐mediated epithelial–mesenchymal transition as a therapeutic target in oral squamous cell carcinoma | |
| Langan et al. | Colorectal cancer biomarkers and the potential role of cancer stem cells | |
| Necela et al. | Folate receptor-α (FOLR1) expression and function in triple negative tumors | |
| Lee et al. | Prediction of recurrence-free survival in postoperative non–small cell lung cancer patients by using an integrated model of clinical information and gene expression | |
| Davidson et al. | Ovarian cancer: diagnostic, biological and prognostic aspects | |
| Bhangu et al. | The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer | |
| Piskol et al. | A clinically applicable gene-expression classifier reveals intrinsic and extrinsic contributions to consensus molecular subtypes in primary and metastatic colon cancer | |
| Yu et al. | Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy | |
| Masuda et al. | Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer | |
| Kraus et al. | Recent advances in personalized colorectal cancer research | |
| Hwang et al. | Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer | |
| Kanda et al. | Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer | |
| Givechian et al. | Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples | |
| Ren et al. | Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients | |
| Dennison et al. | High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype | |
| Jacob et al. | A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer | |
| Baehner et al. | Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy | |
| Ding et al. | Expression of glioma-associated oncogene homolog 1 is associated with invasion and postoperative liver metastasis in colon cancer | |
| Xiao et al. | Non‐invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study |